ClinicalTrials.gg

Pain, Postoperative clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 5,661 studies for Pain, Postoperative across more than 10 countries. 1,237 are recruiting or about to start. 4,508 of them are mainly about Pain, Postoperative (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Phantom Limb too: 5,819 studies, 1,271 open.

ClinicalTrials.gov finds 8,197 studies for Pain, Postoperative. How that becomes 5,648 here

This page counts the studies the registry files under Pain, Postoperative, and those it files under no condition that list Pain, Postoperativethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 8,197Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −154Filed under a narrower condition, counted on its own pagePhantom Limb 154
  3. −80List Pain, Postoperative as a condition, but the registry did not file them under itMost often written as “Postoperative Pain Management” (36), “Post Operative Pain Control” (5), and “Postoperative Pain Control” (5). The registry filed them under other conditions only, most often Pain (21) and Agnosia (20).
  4. −2,315Match it another way1,223 name it in the title, 81 in a keyword, and 1,011 by a synonym or other text the search reads.
  5. 5,648The count on this page166 of them list Pain, Postoperative in their own words; the registry filed them under no condition.

Status

Completed
3,249
Recruiting
678
Status unknown
667
Not yet recruiting
489
Terminated
214
Active, not recruiting
148

Phase

Phase 4
1,075
Phase 3
461
Phase 2
415
Phase 1
130
Early Phase 1
53

Where

United States
1,180
Turkey
1,099
Egypt
595
China
248
Canada
190
Denmark
180

Who develops what

Add Pain, Postoperative to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 16 programs from 15 companies, 16 with this as their studies’ main aim; 4 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Bausch Health Companies and Chengdu Kanghong Pharmaceutical Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BupivacaineRecent, repeated
Evidence
  • NCT06799845 · Allay Therapeutics, Inc. · Phase 2 · comparator · “bupivacaine hydrochloride” · registered Jan 2025
  • NCT06109428 · Heron Therapeutics · Phase 4 · comparator · “Bupivacaine Hydrochloride” · registered Oct 2023
  • NCT06109415 · Heron Therapeutics · Phase 4 · comparator · “Bupivacaine Hydrochloride” · registered Oct 2023
  • NCT05603832 · Arthritis Innovation Corporation · Phase 3 · background · “0.25 % Bupivacaine HCl” · registered Oct 2022
  • NCT05161637 · Taiwan Liposome Company · Phase 3 · live · comparator · “Bupivacain” · registered Dec 2021
Pacira BioSciences, Inc.40% of its industry studiesUS: off-patent, 28 generics marketed45 studies
RopivacaineRecent, repeated
Evidence
  • NCT06574269 · TLC Biopharmaceuticals, Inc. · Phase 2 · live · background · “Ropivacaine” · registered Aug 2024
  • NCT06509958 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Ropivacaine Hydrochloride Injection” · registered Jul 2024
  • NCT05831449 · Cali Pharmaceuticals LLC · Phase 3 · comparator · “Naropin, 0.5% Injectable Solution” · registered Apr 2023
  • NCT05813847 · Cali Pharmaceuticals LLC · Phase 3 · comparator · “local anaesthetic injection of ropivacaine HCl” · registered Apr 2023
  • NCT05769855 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “ropivacaine HCl” · registered Mar 2023
PainReform LTD24% of its industry studiesUS: off-patent, 11 generics marketed46 studies
AcetaminophenRecent, repeated
Evidence
  • NCT07225140 · AFT Pharmaceuticals, Ltd. · Phase 3 · live · comparator · “Acetaminophen 500mg” · registered Oct 2025
  • NCT06109428 · Heron Therapeutics · Phase 4 · background · “MMA regimen” · registered Oct 2023
  • NCT06109415 · Heron Therapeutics · Phase 4 · background · “MMA regimen” · registered Oct 2023
  • NCT05603832 · Arthritis Innovation Corporation · Phase 3 · background · “Acetaminophen” · registered Oct 2022
  • NCT05109312 · Heron Therapeutics · Phase 4 · live · background · “Acetaminophen” · registered Oct 2021
Johnson & Johnson29% of its industry studiesUS: off-patent, 109 generics marketed34 studies
TramadolRecent, repeated
Evidence
  • NCT06780267 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Tramadol Hydrochloride SR Tablets” · registered Jan 2025
  • NCT06215859 · Viatris Inc. · Phase 3 · comparator · “Tramadol” · registered Dec 2023
  • NCT06215820 · Viatris Inc. · Phase 3 · comparator · “Tramadol” · registered Dec 2023
  • NCT05995912 · Laboratorios Liomont · Phase 2 · comparator · “Tramadol” · registered Aug 2023
  • NCT04647435 · Apsen Farmaceutica S.A. · Phase 3 · comparator · “Tramal®” · registered Nov 2020
Johnson & Johnson37% of its industry studiesUS: off-patent, 12 generics marketed34 studies

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
CPL-01☆ Track1 live phase-3 study: NCT07490496Cali Pharmaceuticals LLC
Combogesic® tablets☆ Track1 live phase-3 study: NCT07225140AFT Pharmaceuticals, Ltd.
HL-1186☆ Track2 live phase-3 studies: NCT07709598, NCT07699601Shanghai Huilun Pharmaceutical Co., Ltd.
RopivacaineApproved: US☆ Track1 live phase-3 study: NCT07222748TLC Biopharmaceuticals, Inc.

The 4 in phase 3 with the nearest primary completion, of 16 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Jun 2027 est.CPL-01 · Cali Pharmaceuticals LLC · Phase 3 main aimNCT07490496 Phase 3 Bunionectomy Study — primary endpoint: Postoperative Pain with activity · 112 enrolled
  • Oct 2027 est.Combogesic® tablets · AFT Pharmaceuticals, Ltd. · Phase 3 main aimvs AcetaminophenNCT07225140 A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery — primary endpoint: Time-adjusted summed pain intensity difference (SPID) calculated from the visual analogue scale (VAS) pain intensity scores 6 hours after first dose of study medication · 180 enrolled
  • Oct 2027 est.CYT-1010 · Cytogel Pharma, LLC · Phase 2 main aimNCT07905105 A Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction — primary endpoint: Number of Participants With Treatment-Emergent Adverse Events · 32 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pain, Postoperative studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 87 open · Opioids 52 open · Corticosteroids 34 open · NSAIDs 22 open · COX-2 inhibitors 5 open

Coming up

536studies finish main data collection within a year25 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger. 74 (11%) take children under 18. 91 (13%) are for women only and 8 (1%) for men only; 128 (19%) take healthy volunteers.

Recruiting studies that take each age, of 676
AgeWomenMen
1039 (6%)37 (5%)
18544 (80%)475 (70%)
30596 (88%)513 (76%)
40597 (88%)514 (76%)
50572 (85%)502 (74%)
65526 (78%)465 (69%)
75394 (58%)354 (52%)
85285 (42%)256 (38%)

Across all 5,654 studies, recruiting or not: 50% stop at 75 or younger and 38% at 65; 13% take children; 16% are for women only and 2% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pain, Postoperative studies take

Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 116 mo6–27 · 83 studies—18 mo8–30 · 65 studies
Phase 212 mo6–24 · 139 studies7 mo3–11 · 49 studies19 mo9–32 · 90 studies
Phase 2/317 mo10–41 · 52 studies—17 mo11–41 · 49 studies
Phase 317 mo8–30 · 167 studies13 mo6–19 · 43 studies20 mo10–40 · 124 studies
Phase 416 mo8–32 · 542 studies—16 mo8–32 · 532 studies
Interventional, no phase11 mo6–23 · 2,110 studies—11 mo6–23 · 2,097 studies
Observational13 mo5–33 · 395 studies—12 mo5–32 · 391 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting21

Show 16 more

Newly registered100

Show 45 more

and 50 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 5,661. Browse all 5,661 → or search them.